1. Home
  2. NUVL vs PIPR Comparison

NUVL vs PIPR Comparison

Compare NUVL & PIPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NUVL
  • PIPR
  • Stock Information
  • Founded
  • NUVL 2017
  • PIPR 1895
  • Country
  • NUVL United States
  • PIPR United States
  • Employees
  • NUVL N/A
  • PIPR N/A
  • Industry
  • NUVL Biotechnology: Pharmaceutical Preparations
  • PIPR Investment Bankers/Brokers/Service
  • Sector
  • NUVL Health Care
  • PIPR Finance
  • Exchange
  • NUVL Nasdaq
  • PIPR Nasdaq
  • Market Cap
  • NUVL 5.8B
  • PIPR 5.2B
  • IPO Year
  • NUVL 2021
  • PIPR N/A
  • Fundamental
  • Price
  • NUVL $78.64
  • PIPR $354.63
  • Analyst Decision
  • NUVL Strong Buy
  • PIPR Hold
  • Analyst Count
  • NUVL 11
  • PIPR 4
  • Target Price
  • NUVL $120.91
  • PIPR $312.50
  • AVG Volume (30 Days)
  • NUVL 390.3K
  • PIPR 114.8K
  • Earning Date
  • NUVL 11-11-2025
  • PIPR 10-24-2025
  • Dividend Yield
  • NUVL N/A
  • PIPR 1.64%
  • EPS Growth
  • NUVL N/A
  • PIPR 55.41
  • EPS
  • NUVL N/A
  • PIPR 11.86
  • Revenue
  • NUVL N/A
  • PIPR $1,597,729,000.00
  • Revenue This Year
  • NUVL N/A
  • PIPR $13.44
  • Revenue Next Year
  • NUVL N/A
  • PIPR $14.27
  • P/E Ratio
  • NUVL N/A
  • PIPR $29.91
  • Revenue Growth
  • NUVL N/A
  • PIPR 10.68
  • 52 Week Low
  • NUVL $55.54
  • PIPR $202.91
  • 52 Week High
  • NUVL $110.00
  • PIPR $360.00
  • Technical
  • Relative Strength Index (RSI)
  • NUVL 51.21
  • PIPR 67.49
  • Support Level
  • NUVL $77.88
  • PIPR $343.00
  • Resistance Level
  • NUVL $83.09
  • PIPR $352.34
  • Average True Range (ATR)
  • NUVL 3.14
  • PIPR 7.61
  • MACD
  • NUVL 0.14
  • PIPR 1.22
  • Stochastic Oscillator
  • NUVL 48.79
  • PIPR 86.93

About NUVL Nuvalent Inc.

Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.

About PIPR Piper Sandler Companies

Piper Sandler Cos is an investment bank and institutional securities firm, serving the needs of corporations, private equity groups, public entities, non-profit entities and institutional investors in the United States (U.S.) and internationally. The company provides a broad set of products and services, including financial advisory services; equity and debt capital markets products; public finance services; institutional brokerage services; fundamental equity and macro research services; fixed income services; and alternative asset management strategies. It generates maximum revenue from Advisory services followed by Equity financing.

Share on Social Networks: